Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Side-effects news

Show

From To
Switching to new tenofovir alafenamide keeps virus in check and improves kidney and bone health

People who switch from the current version of tenofovir to tenofovir alafenamide (TAF) – a new formulation that reaches higher levels in HIV-infected cells – maintained undetectable

Published
28 July 2015
By
Liz Highleyman
New NNRTI doravirine suppresses HIV as well as efavirenz but with fewer central nervous system side-effects

Merck's next-generation NNRTI doravirine (formerly known as MK-1439) was found to be as effective as efavirenz at suppressing HIV replication, but half as many study participants taking doravirine experienced drug-related

Published
23 July 2015
By
Liz Highleyman
Five antiretroviral combinations associated with increased risk of a cardiovascular event

Treatment with four individual and five combinations of anti-HIV drugs is associated with an increased risk of a cardiovascular event, investigators from the United States report in the

Published
08 May 2015
By
Michael Carter
US guidelines shift to integrase-based combinations for first-line treatment: Atripla relegated due to side effects

The rationale for dropping Atripla is due to concerns about the tolerability of efavirenz, especially the high rate of central nervous system related toxicities. Although this has been a long-standing community concern, DHHS guidelines have consistently recommended efavirenz in previous editions. This tolerability statement is made in the year that efavirenz comes off patent.

Published
06 May 2015
From
i-Base
Ritonavir concentrations not correlated with lipid levels in people with HIV taking boosted atazanavir or boosted darunavir

People taking HIV treatment based on ritonavir-boosted atazanavir and darunavir have comparable long-term increases in lipid levels, investigators from the United States report in the online edition of

Published
06 April 2015
By
Michael Carter
Chinese study sheds light on how well treatment may work as prevention in the real world

A study from the Henan province of China published recently shows that antiretroviral therapy (ART) may not be as effective at suppressing HIV and preventing onward transmission

Published
01 April 2015
By
Gus Cairns
Predictors of HIV-related peripheral neuropathy in the modern era

Researchers at major clinical centres in the U.S. have collaborated to study potential causes of peripheral neuropathy (PN) among HIV-positive people in the modern era. They recruited about 500 people who were free from PN and monitored them for an average of two years, performing extensive assessments. Taking into account many issues, statistical analysis found that there were several factors associated with an increased risk for PN.

Published
01 April 2015
From
CATIE
Most HIV-positive gay men in European survey are on HIV treatment, though fewer in the east

The large EMIS survey of gay men living in Europe has found that over 70% of respondents with HIV are taking antiretroviral therapy (ART). Of those who

Published
30 March 2015
By
Gus Cairns
Does HIV make you fat? Study connects viral load with fat gains

HIV infection, or inflammatory changes associated with it, may be responsible for fat accumulation and body fat redistribution, rather than HIV drugs, the Conference on Retroviruses and

Published
06 March 2015
By
Gus Cairns
Tenofovir, boosted atazanavir and boosted lopinavir are associated with cumulative risk of developing chronic kidney disease

Three antiretroviral drugs are associated with a slowly increasing rate of chronic kidney disease over time, the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in

Published
27 February 2015
By
Gus Cairns
← First12345...72Next →

Filter by country